Abstract:Importance: It is critically important to improve our ability to diagnose and track Alzheimer disease (AD) as early as possible. Individuals with autosomal dominant forms of AD can provide clues as to which and when biological changes are reliably present prior to the onset of clinical symptoms.Objective: To characterize the associations between amyloid and tau deposits in the brains of cognitively unimpaired and impaired carriers of presenilin 1 (PSEN1) E280A mutation.Design, Setting, and Participants: In this cross-sectional imaging study, we leveraged data from a homogeneous autosomal dominant AD kindred, which allowed us to examine measurable tau deposition as a function of individuals' proximity to the expected onset of dementia. Cross-sectional measures of carbon 11-labeled Pittsburgh Compound B positron emission tomography (PET) and flortaucipir F 18 (previously known as AV 1451, T807) PET imaging were assessed in 24 PSEN1 E280A kindred members (age range, 28-55 years), including 12 carriers, 9 of whom were cognitively unimpaired and 3 of whom had mild cognitive impairment, and 12 cognitively unimpaired noncarriers.Main Outcomes and Measures: We compared carbon 11-labeled Pittsburgh Compound B PET cerebral with cerebellar distribution volume ratios as well as flortaucipir F 18 PET cerebral with cerebellar standardized uptake value ratios in mutation carriers and noncarriers. Spearman correlations characterized the associations between age and mean cortical Pittsburgh Compound B distribution volume ratio levels or regional flortaucipir standardized uptake value ratio levels in both groups.Results: Of the 24 individuals, the mean (SD) age was 38.0 (7.4) years, or approximately 6 years younger than the expected onset of clinical symptoms in carriers. Compared with noncarriers, cognitively unimpaired mutation carriers had elevated mean cortical Pittsburgh Compound B distribution volume ratio levels in their late 20s, and 7 of 9 carriers older than 30 years reached the threshold for amyloidosis (distribution volume ratio level > 1.2). Elevated levels of tau deposition were seen within medial temporal lobe regions in amyloid-positive mutation carriers 6 years before clinical onset of AD in this kindred. Substantial tau deposition in the neocortex was only observed in 1 unimpaired carrier and in those with mild cognitive impairment. β-Amyloid uptake levels were diffusely elevated in unimpaired carriers approximately 15 years prior to expected onset of mild cognitive impairment. In carriers, higher levels of tau deposition were associated with worse performance on the Mini-Mental State Examination (entorhinal cortex: r = -0.60; P = .04; inferior temporal lobe: r = -0.54; P = .06) and the Consortium to Establish a Registry for Alzheimer Disease Word List Delayed Recall (entorhinal cortex: r = -0.86; P < .001; inferior temporal lobe: r = -0.70; P = .01).Conclusions and Relevance: The present findings add to the growing evidence that molecular markers can characterize biological changes associated with AD in individuals who are still cognitively unimpaired. The findings also suggest that tau PET imaging may be useful as a biomarker to distinguish individuals at high risk to develop the clinical symptoms of AD and to track disease progression.

Genetic Influences on White Matter and Metabolism Abnormal Change in Alzheimer's Disease: Meta-analysis for Neuroimaging Research on Presenilin 1 Mutation

Presenilin-1 mutation is associated with a hippocampus defect in alzheimer's disease: Meta-Analysis for neuroimaging research

A Novel PSEN1 M139L Mutation Found in a Chinese Pedigree with Early-Onset Alzheimer's Disease Increases Aβ42/Aβ40 Ratio.

Clinical And Neuroimaging Characterization Of Chinese Dementia Patients With Psen1 And Psen2 Mutations

Presenilin‐1 mutation position influences amyloidosis, small vessel disease, and dementia with disease stage

Associations Between Biomarkers and Age in the Presenilin 1 E280A Autosomal Dominant Alzheimer Disease Kindred: a Cross-Sectional Study.

Association Between Amyloid and Tau Accumulation in Young Adults With Autosomal Dominant Alzheimer Disease

P-tau and Neurodegeneration Mediate the Effect of Β-Amyloid on Cognition in Non-Demented Elders

Shared and unique effects of ApoEε4 and pathogenic gene mutation on cognition and imaging in preclinical familial Alzheimer's disease

Altered Spontaneous Brain Activity Pattern in Cognitively Normal Young Adults Carrying Mutations of APP, Presenilin-1/2 and APOE Ε4.

Shared and Unique Effects of ApoEε4 and Pathogenic Gene Mutation on Cognition and Imaging in Preclinical Familial Alzheimer’s Disease

Association of Presynaptic Loss with Alzheimer's Disease and Cognitive Decline.

Brain Imaging and Fluid Biomarker Analysis in Young Adults at Genetic Risk for Autosomal Dominant Alzheimer's Disease in the Presenilin 1 E280A Kindred: a Case-Control Study.

Two novel presenilin-1 mutations (I249L and P433S) in early onset Chinese Alzheimer's pedigrees and their functional characterization.

Genome-Wide Association Study of Brain Alzheimer's Disease-Related Metabolic Decline As Measured by [18F] FDG-PET Imaging.

P4–068: Pre‐symptomatic Functional Brain Changes in PS1 E280A Mutation Carriers Compared with Other Biomarkers: Pilot Data from the Alzheimer's Prevention Initiative Biomarker Project

P3-395: Mean Age-of-onset of Familial Alzheimer Disease Caused by Presenilin Mutations Correlates with Both Increased Aβ42 and Decreased Aβ40

Basal forebrain volume and metabolism in carriers of the Colombian mutation for autosomal dominant Alzheimer's disease

P3‐399: ASSOCIATION BETWEEN CORTICAL THINNING AND TAU PATHOLOGY IN PRECLINICAL AUTOSOMAL DOMINANT ALZHEIMER'S DISEASE

P2‐017: Mutation Frequency of Pathogenic Genes in Familial Alzheimer's Disease in China

Alzheimer's disease genetic risk and changes in brain atrophy and white matter hyperintensities in cognitively unimpaired adults